Phase I Trial Design

190207_PhaseIDesign

Category: News & Announcements 2019By PharmAust 06/02/2019

Morgans – PharmAust Research Note
12/08/2024
Morgans – PharmAust Research Note
08/07/2024
Stockhead – PharmAust’s monepantel drug could be a game-changer for MND/ALS patients, new data shows
05/06/2024
Small Caps – PharmAust encouraged by positive monepantel survival rate assessment
05/06/2024

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust @pharmaust ·

24 Jun

📸 Highlights from the MND Australia Global Day Event at Parliament House!

We teamed up with FightMND to raise awareness and fight for a future free of Motor Neurone Disease. 💙

#MNDAustralia #FightMND #MNDGlobalDay

Reply on Twitter 1805134834358210569 Retweet on Twitter 1805134834358210569 2 Like on Twitter 1805134834358210569 12 Twitter 1805134834358210569

Retweet on Twitter PharmAust Retweeted

Stockhead @stockheadau ·

21 Jun

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
#ASX @PharmAust

Reply on Twitter 1803984607676654065 Retweet on Twitter 1803984607676654065 1 Like on Twitter 1803984607676654065 3 Twitter 1803984607676654065

PharmAust @pharmaust ·

21 Jun

Exciting news for our investors! 🎉 Check out the details of our latest capital raise here: https://investorhub.pharmaust.com/investment-offer/32. Thank you for your continued support! 🌟 #PharmAust

Reply on Twitter 1804030728956711230 Retweet on Twitter 1804030728956711230 2 Like on Twitter 1804030728956711230 7 Twitter 1804030728956711230

nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top

Phase I Trial Design

Related posts